Paul R. Edick

Biography

Paul R. Edick was most recently Founding Partner of 3G Advisors, a consultancy to the Pharmaceutical, Healthcare and Healthcare Investor communities. From July 2010 until November 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (DRTX), a public biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata’s lead product, Dalvance®, was launched in July of 2014. Durata, originally founded by a premier team of venture capital organizations, (New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners), went public in July 2012 and was acquired by Actavis PLC in November 2014. Prior to starting Durata, Mr. Edick was CEO of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was CEO of MedPointe Healthcare Inc., a U.S. based specialty pharmaceutical company, a position he assumed in Q1 of 2006, having been President of Pharmaceutical Operations since Q1 of 2002. Mr. Edick led the growth of the business, the development of a clinical stage portfolio and the negotiated sale of MedPointe to Meda, AB of Sweden in Q3 of 2007. ​ Mr. Edick also has extensive industry experience with leading consumer, pharmaceutical and healthcare organizations. From 1978 to 1994, Mr. Edick held sales, marketing, advertising and advisory positions in Procter & Gamble, Ortho Pharmaceutical and The Hamilton Group. Between 1994 and 2002, in a series of positions at G. D. Searle and its acquirer, Pharmacia Corporation, he led Searle's U.S. managed care organization (1994-1995), its U.S. marketing organization (1995-1996), and its Global Pain & Inflammation Business, including the commercialization and launch planning for Celebrex® (1996-1997). In 1998, Mr. Edick was named Searle's VP, Canada & Latin America Operations. In 1999, Mr. Edick became President of Asia Pacific, Canada & Latin America Operations. In 2000, upon Pharmacia's acquisition of Searle, Mr. Edick was named Group Vice President and President, Asia Pacific & Latin America Operations at Pharmacia. ​ Mr. Edick has also served on a number of pharmaceutical and healthcare company boards, including; as a Director (7/2010-11/2014) of Durata Therapeutics Inc., a U.S. public biotech company; as a Director (4/2013-5/2016) of Circassia, Ltd., a U.K. public Biotech company; as a Director (5/2008-5/2011) and Chairman (5/2009-5/2011) of Life Cycle Pharma Ltd., (now Veloxis), a Danish public biotech company; as a Director (2/2006-1/2013) of Amerita, Inc., a private U.S. Home Health provider; and, as a Director (7/2005-4/2011) of IMC, a private U.S. medical communications company. ​ Mr. Edick continues to serve, since August 1, 2016, as a Director of Sucampo Pharmaceutical, Inc., a public U.S. Specialty Pharma company; since July 2011, as a Director of NewLink Genetics, Inc., a U.S. public Biotech company; since June 2015, as a Director of Neos Therapeutics, Inc., a public U.S. biopharma company; since September 2015, as a Director of PDL Biopharma, Inc., a public U.S. provider of structured debt to the pharma and biopharma industry; and, since October 2015, as a Board Chairman of Iterum Therapeutics, Ltd., a private Irish Biotech company. ​ Mr. Edick holds a BA in Psychology from Hamilton College in Clinton, NY.

Research Interest

Mr. Edick has also served on a number of pharmaceutical and healthcare company boards, including; as a Director (7/2010-11/2014) of Durata Therapeutics Inc., a U.S. public biotech company; as a Director (4/2013-5/2016) of Circassia, Ltd., a U.K. public Biotech company; as a Director (5/2008-5/2011) and Chairman (5/2009-5/2011) of Life Cycle Pharma Ltd., (now Veloxis), a Danish public biotech company; as a Director (2/2006-1/2013) of Amerita, Inc., a private U.S. Home Health provider; and, as a Director (7/2005-4/2011) of IMC, a private U.S. medical communications company.